Valeant's former CEO may remain as consultant through 2017

NEW YORK, May 31 (Reuters) - Michael Pearson, the former chief executive officer of Valeant Pharmaceuticals International , has signed a consulting agreement with the drugmaker that will run through 2017 and pay him hundreds of thousands of dollars, according to the separation agreement filed with regulators.